Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulindac in Preventing Melanoma
NCT00841204Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing Sulindac with Placebo (2 arms). Primary endpoints: Sulindac Concentration in the Nevi at 8 weeks, Sulindac Sulfone Concentration in the Nevi at 8 weeks and 1 more. Started Feb 2009; status: completed.
02
Drugs
sulindac
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00841204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841204.